Skip to main content

UBS Group AG

Position in ELVN — Enliven Therapeutics, Inc.

CIK 1610520 ZURICH, V8

Position in ELVN

as of Jun 30, 2026 · filed Aug 13, 2026
Position Value
$17,362,335
+$6,247,411 QoQ
Shares Held
342,115
+20.7% QoQ
Ownership
0.467%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#48
of 210 holders
Holding Since
Mar 2023
13 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in ELVN Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Jun 30, 2026

UBS Group AG holds $8,751,270,183 across 562 Biotechnology names. ELVN ranks #88 (0.2% of the industry book) .

# Ticker Company Shares Value (USD) Open

All Filings in ELVN

Export CSV
13 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $17,362,335 342,115
2026-03-31 $11,114,924 283,544
2025-12-31 $891,167 57,868
2025-09-30 $1,627,527 79,508
2025-06-30 $2,773,896 138,280
2025-03-31 $1,386,180 70,436
2024-12-31 $1,961,730 87,188
2024-09-30 $706,997 27,682
2024-06-30 $470,157 20,118
2024-03-31 $472,027 26,835
2023-09-30 $1,433 105
2023-06-30 $1,653 81
2023-03-31 $7,313 334